Gøtzsche P C
Liver Unit, Hvidovre Hospital, Denmark.
Lancet. 1989 Jan 14;1(8629):88-91. doi: 10.1016/s0140-6736(89)91439-6.
Meta-analysis was used to study patients' preference in 37 crossover trials that compared indomethacin with newer non-steroidal, antiinflammatory drugs (NSAIDs). 3 reports did not present numerical data. Patients who withdrew from the trial were included in the analysis. The difference between the proportion of patients who preferred the new drug and the proportion who preferred indomethacin (the therapeutic gain) was 14%. After exclusion of 2 unreliable studies the therapeutic gain was only 7%, and when 4 preliminary reports were also ignored, the gain was 5% (95% confidence interval 0 to 10%). In two additional analyses in which the 2 outlying results were excluded, the gain was also 5%. The findings do not support the trend to replace indomethacin with newer NSAIDs.
荟萃分析用于研究37项交叉试验中患者对吲哚美辛与新型非甾体抗炎药（NSAIDs）的偏好。3份报告未提供数值数据。退出试验的患者被纳入分析。偏好新药的患者比例与偏好吲哚美辛的患者比例之间的差异（治疗获益）为14%。排除2项不可靠研究后，治疗获益仅为7%，若同时忽略4份初步报告，获益为5%（95%置信区间0至10%）。在另外两项排除了2个异常结果的分析中，获益也为5%。这些发现不支持用新型NSAIDs取代吲哚美辛的趋势。
